Helix BioPharma Strengthens Leadership with Strategic Executive Appointments

Helix BioPharma Corp. has announced the appointments of Veronika Kandziora as Chief Operating Officer and Dr. Jessica Kourniaktis as Director of Communications, strategic moves designed to bolster the company's operational capabilities and communication strategy in its quest to develop treatments for hard-to-treat cancers.

Kandziora brings over 20 years of leadership experience across biopharma, financial, and consulting sectors. With a strong background in finance, compliance, and corporate strategy, she previously served as the company's Corporate Secretary and strategic consultant. Her appointment aims to bring structural clarity and strategic alignment to Helix's organizational operations.

Dr. Kourniaktis, a communications strategist with a decade of experience in life sciences, will focus on articulating the company's vision and engaging critical stakeholders. Her background includes leadership roles in multiple biopharma startups and a distinguished academic career, having completed her DPhil from the University of Oxford.

CEO Thomas Mehrling emphasized the significance of these appointments, noting that Kandziora and Kourniaktis will strengthen the leadership team during a critical phase of the company's development. The new executives are expected to support Helix's mission of developing innovative oncology treatments, particularly its lead candidate L-DOS47, an antibody-enzyme conjugate targeting solid tumors.

These appointments signal Helix BioPharma's commitment to advancing its clinical-stage oncology research and improving communication about its innovative approach to treating challenging cancer types. The strategic leadership additions reflect the company's focus on operational excellence and effective stakeholder engagement.